Maybe not material, but from a risk management perspective, having multiple products on the market, each contributing a little to EBITDA, then if one drug is recalled, the business impact is not as great. If CSL only had a few products in the market, the risk of the impact of a recall is much much greater.
HT1
Maybe not material, but from a risk management perspective,...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$308.05 |
Change
2.510(0.82%) |
Mkt cap ! $148.8B | |||
| Open | High | Low | Value | Volume |
| $307.94 | $309.48 | $306.35 | $254.8M | 840.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 268 | $307.92 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $308.23 | 139 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |